Interim analysis of a phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer

被引：0
|
作者：
Luck, HJ
Thomssen, C
duBois, A
Lisboa, BW
Untch, M
Kuhnle, H
Konecny, G
Janicke, F
Meerpohl, HG
Lindner, C
Hecker, D
Diergarten, K
机构：
[1] TECH UNIV MUNICH,FRAUENKLIN,W-8000 MUNICH,GERMANY
[2] LUDWIG LEOPOLD UNIV,FRAUENKLIN,MUNICH,GERMANY
[3] UNIV MUNICH,MUNICH,GERMANY
[4] ST VINCENTIUS KRANKENHAUS,KARLSRUHE,GERMANY
[5] BRISTOL MYERS SQUIBB CO,MUNICH,GERMANY
来源：
SEMINARS IN ONCOLOGY | 1996年 / 23卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：33 / 36
页数：4
相关论文
共 50 条
  • [1] Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer
    Luck, HJ
    Thomssen, C
    duBois, A
    Untch, M
    Lisboa, B
    Kohler, G
    Diergarten, K
    SEMINARS IN ONCOLOGY, 1997, 24 (05) : 35 - 39
  • [2] Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer
    Luck, HJ
    Thomssen, C
    duBois, A
    Lisboa, BW
    Untch, M
    Kuhnle, H
    Janicke, F
    Meerpohl, HG
    Lindner, C
    Kcnecny, G
    Hecker, D
    Diergarten, K
    SEMINARS IN ONCOLOGY, 1997, 24 (01) : S13 - S16
  • [3] Vinorelbine, epirubicin and fluorouracil as first-line therapy in metastatic breast cancer - A phase II trial
    Elomaa, I
    Joensuu, H
    Blomqvist, C
    ACTA ONCOLOGICA, 2003, 42 (04) : 309 - 314
  • [4] First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study
    Allouache, D
    Gawande, SR
    Tubiana-Hulin, M
    Tubiana-Mathieu, N
    Piperno-Neumann, S
    Mefti, F
    Bozec, L
    Genot, JY
    BMC CANCER, 2005, 5 (1)
  • [5] First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study
    Djelila Allouache
    Sulochana R Gawande
    Michele Tubiana-Hulin
    Nicole Tubiana-Mathieu
    Sophie Piperno-Neumann
    Fawzia Mefti
    Laurence Bozec
    Jean-Yves Genot
    BMC Cancer, 5
  • [6] Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study
    Einbeigi, Z.
    Bergstrom, D.
    Hatschek, T.
    Malmberg, M.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2008, 2 : 533 - 538
  • [7] Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy
    Gennari, A
    Bruzzi, P
    Orlandini, C
    Salvadori, B
    Donati, S
    Landucci, E
    Guarneri, V
    Rondini, M
    Ricci, S
    Conte, P
    BRITISH JOURNAL OF CANCER, 2004, 90 (05) : 962 - 967
  • [8] Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy
    A Gennari
    P Bruzzi
    C Orlandini
    B Salvadori
    S Donati
    E Landucci
    V Guarneri
    M Rondini
    S Ricci
    P Conte
    British Journal of Cancer, 2004, 90 : 962 - 967
  • [9] Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer
    Blum, Joanne L.
    Dees, E. Claire
    Chacko, Aparna
    Doane, Lisa
    Ethirajan, Sukumar
    Hopkins, Judith
    McMahon, Richard
    Merten, Suzan
    Negron, Angel
    Neubauer, Marcus
    Ilegbodu, Des
    Boehm, Kristi A.
    Asmar, Lina
    O'Shaughnessy, Joyce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) : 4384 - 4390
  • [10] A phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer (MBC): Interim safety results
    Brufsky, A. M.
    Hoelzer, K. L.
    Keaton, M. R.
    Beck, J. T.
    Krill-Jackson, E.
    Wang, Y.
    Hu, S.
    Vaughn, L. G.
    Shonukan, O. O.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345